The conjugation of monoclonal antibodies (mAbs), or their Fab fragments against HER2, improved drug delivery to tumor sites and showed therapeutic efficacy in various HER2-overexpressing mouse xenograft models [184,185]. Here, ERBB2 is linked to neoplasm.